Gurgaon (Haryana) India, January 19, 2010

Ranbaxy Laboratories Limited (Ranbaxy) today announced the signing of Agreements with Biovel Lifesciences Private Limited (Biovel), Bangalore, India, providing for the acquisition of product rights and a manufacturing facility, from Biovel.

The proposed transaction will give Ranbaxy access to all of Biovel’s products, pipeline, IP, Know-How and manufacturing facility, located in Bangalore, India.

Speaking on the development, Mr. Atul Sobti, CEO & MD, Ranbaxy, said, “With an increasing focus on prevention of disease, the importance of the vaccine market has never been greater. This transaction with Biovel provides us an entry platform to manufacture vaccines as well as biotherapeutics. The vaccine and biotherapeutics business will be an important part of our growth strategy.”

Commenting on the transaction, Mr. Pratap Reddy, Chairman, Biovel, said, “We have created modern manufacturing infrastructure and a robust product pipeline. We are sure that Ranbaxy, with its global market reach, quality and manufacturing expertise, will be able to leverage this to its full potential, and create a business of scale.”

The products that are part of the transaction include Typhoid Vi antigen and Hib conjugate vaccines, for which, Biovel has received regulatory approval for India; as well as Biovel’s development pipeline, comprising a range of vaccines, biotherapeutics and other products.

In 2008, the global vaccines market was approximately USD 21 billion. It is estimated to grow at a rate of 9%, to reach USD 34 billion by 2014. The Indian vaccine market valued at Rs. 3,600 Crores, in 2008, is growing annually at 10%. [Evaluate Report, 2009].

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.